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INTRODUCTION: 
Hypertension is a major cause of cardiovascular 
diseases worldwide and hence responsible for increased 
morbidity and mortality.
1
 The overactivation of Renin 
Angiotensin System (RAS) results in increased 
synthesis of Angiotensin II which has vasopressor 
action and is strongly involved in the pathogenesis of 
hypertension. Along with hypertension insulin 
resistance is another important component of metabolic 
syndrome
2
 and both of these are two independent 
predisposing risk factors for diabetes and also a strong 
association exists between these two.
3
 As per JNC VII 
guidelines goal to treat the hypertensive patients has 
been set to minimize the risk in such patients who 
develop serious cardiovascular complications. These 
goals can be achieved by proper treatment with 
antihypertensive drugs and improving the life style of 
the patients.
4
 A number of drugs like centrally acting 
agents, angiotensin receptor blockers
5,6
, angiotensin 
converting enzyme inhibitors, calcium channel 
blockers, diuretics and β blockers etc. are used to treat 
this disorder. Out of all these anti-hypertensives, β-
blockers and diuretics (Thiazide and loop diuretics) can 
cause hyperglycemia and impairment of lipid profile
7
.  
Moxonidine being an selective imidazoline receptor 
agonist, stimulates the imidazoline type1 receptors in 
cardiovascular regulatory centres of the medulla and  
inhibits central sympathetic activity that leads to 
decrease  in blood pressure. It also improves insulin 
sensitivity in patients of metabolic syndrome.
8
 Recent 
in vitro data indicates that Telmisartan activates 
peroxisome proliferator–activated receptor c (PPAR-c) 
and increase adiponectin protein content in adipocytes. 
By this means, it may improve insulin sensitivity in 
vivo.
9
 
ABSTRACT:  
Background: Hypertension being a major cause of cardiovascular diseases worldwide is associated with the overactivation of 
Renin Angiotensin System (RAS). Both hypertension and insulin resistance are important components of metabolic syndrome 
and a strong association exists between these two. Some of Previous studies conducted on Moxonidine and Telmisartan 
suggest, these agents have a better efficacy and safety profile than other antihypertensives The present study is an effort to 
focus on the effectiveness of these drugs on hypertensive people of Majha region of Punjab, India.  
Aim: To compare the effects of both drugs as monotherapy on the various parameters of blood pressure, insulin resistance and 
lipid profile.  
Material and Methods: It was a randomized (1:1), open label, parallel, comparative study. Moxonidine 0.3 mg in one group 
(A) (n=30) and telmisartan 40 mg in other group (B) (n=30) were used daily for 12 weeks in hypertensive patients. Patients 
were evaluated at day 0 and at 12 weeks.  
Results: Fall in SBP levels by 9.5% in group-A and 7.4% in group-B (p<0.0001) was observed while DBP levels decreased by 
8.9% (p<0.0001) in group A and by 5.6% (p<0.01) in group B. HOMA-IR value was drop by 7.0 % and 7.2 % in group A and 
B respectively. A mean fall of 8% in TC levels (p<0.0001) and a mean fall of 10 % in LDL-C levels was observed in group B. 
In group A, reduction of 12.5 % (p<0.0001) in TG levels was observed. BP goal to achieve SBP <140 mm Hg and DBP < 90 
was attained in 24 patients in group A and 20 patients in group B. 
Conclusion: Moxonidine is slightly better as an antihypertensive than Telmisartan. At the same time, telmisartan has additional 
favourable effects on lipid profile (total cholesterol, LDL-C) 
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According to the various studies conducted in various 
countries, angiotensin receptor blockers
10
 and centrally 
acting agents have been found to have a better safety 
profile than other antihypertensives. Few studies have 
been made in India and this study has been made 
keeping in view the people of North India especially the 
Punjabis of Majha-region because their socio-economic 
background and standard of living is quite different 
from the people of Western countries. 
The present study is meant to see the effects of the 
Moxonidine (newer antihypertensive) and Telmisartan 
as monotherapy on insulin resistance and blood pressure 
and  goals achieved according to JNC VII guidelines. 
METHODOLOGY: 
This was a randomized, open-label, parallel study, 
conducted to assess the effects of Moxonidine (0.3 mg) 
and Telmisartan (40 mg) as monotherapy daily for 12 
weeks. 60 patients (30 in each group) of hypertension, 
aged >18 years of either sex, were selected visiting the 
OPD of Department of Medicine, Govt. Medical 
College, Amritsar. This study has already been 
approved by the Institutional Ethical Committee. 
Patient’s written consent was taken before the 
commencement of the study. Both the study drugs have 
been allocated among the patients randomly. Patients 
were evaluated at day 0 and then at 12 weeks for 
clinical examination, lipid profile, insulin resistance and 
other parameters while blood pressure was recorded on 
every visit i.e. biweekly. 
Inclusion: Patients of either sex with Age>18 years, 
hypertensive patients as diagnosed according to JNC 7 
guidelines and with fasting blood sugar ≤ 125 mg/dl 
were eligible for participation in the study and patients 
with age<18 years, those having diabetes mellitus, 
secondary hypertension, severe cardiovascular 
disorders, those taking steroid or hormonal therapy, 
hepatic, renal and thyroid disorders and pregnant 
women were excluded from the study. 
 
Flowchart: 
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Statistical Analyses: The data were expressed as mean 
± standard deviation (SD) and mean percentage change. 
Treatment effects were tested with a paired student’s ‘t’ 
test. 
RESULTS: 
Baseline characteristics (Table I) and baseline levels of 
different parameters (Table II) of the group A and group 
B were compared at the start of therapy. The difference 
in both the groups was statistically insignificant 
(p>0.05) at baseline (0 day).   
Monotherapy of Moxonidine and Telmisartan in group 
A and group B showed significant fall in systolic and 
diastolic blood pressures at 12 weeks(Table III). Both 
the drugs also showed significant fall in levels of fasting 
blood glucose, fasting plasma insulin and HOMA-IR. 
In group A, patients had more fall in levels of FBG and 
FPI as compared to fall in group B patients while levels 
of HOMA-IR showed equivalent fall in both the 
groups(Table III).Patients of group A showed a 
significant fall in TGs level and patients of group B 
showed a significant fall in levels of TC and LDL-C. 
BP goal to achieve SBP <140 mm Hg and DBP < 90 
was attained in 24 patients(80%) in group A and 20 
patients(
˷
 67%) in group B. 
Side effects: In group A (Moxonidine), Sedation in 
13% (4) patients, dryness of mouth in 10 % (3) patients 
and headache in 6 % (2) patients was observed, while, 
in group B (Telmisartan), dry cough in 13 % (4) 
patients was observed. None of the serious adverse 
events observed in both the treatment groups.
 
 
TABLE-I 
Baseline Characteristics Group- A Group- B 
Age (yrs) 57.4 ± 10 54.06 ± 9.1 
Sex (Male:Female) 13:17 15:15 
Hypertension Newly diagnosed 13 12 
Previously diagnosed 17 18 
Family history of 
Hypertension 
Positive 15 16 
Negative 7 6 
Unknown 8 8 
Family history of 
Diabetes 
Positive 8 7 
Negative 16 18 
Unknown 6 5 
 
 
TABLE- II 
Baseline Parameters Values 
Parameters Group-A Group-B p-values 
Blood Pressure (mm Hg) SBP 148±13 147 ± 7 p>0.05 
DBP 90 ± 9 90 ± 8 p>0.05 
Heart Rate(per minute) 86 ± 5 85 ± 4 p>0.05 
BMI(kg/m2) 27 ± 4 26 ± 3 p>0.05 
Hip Circumference(cm) 98 ± 9 97 ± 6 p>0.05 
FBG (mg/dl) 103 ± 11 105 ± 13 p>0.05 
FPI(µU/ml) 10 ± 1 10 ± 1 p>0.05 
HOMA-IR 2 ± 0.4 3 ± 0.4 p>0.05 
TC (mg/dl) 214 ± 21 218 ± 25 p>0.05 
HDL-C (mg/dl) 44 ± 5 47 ± 7 p>0.05 
LDL-C (mg/dl) 133 ± 20 137 ± 23 p>0.05 
TG (mg/dl) 168 ± 30 172 ± 19 p>0.05 
*value in mean ± S.D 
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TABLE-III 
 
Mean percentage change in the parameters at 12 weeks 
 Moxonidine Group Telmisartan Group 
Parameters 12 weeks 12 weeks 
SBP -9.5% (p<0.0001) -7.4 (p<0.0001) 
DBP -8.9 (p<0.0001) -5.6 (p= 0.002) 
FBG (mg/dl) -5 (p<0.05) -3.7 (p<0.05) 
FPI(µU/ml) -11.5 (p<0.0001) -5 (p < 0.0008) 
HOMA-IR -7.0 (p<0.05) -7.2 (p < 0.002) 
TC (mg/dl) -3 (p = 0.2) -8 (p <0.0001) 
HDL-C (mg/dl) +1.8 (p = 0.6) -5 (p = 0.1) 
LDL-C (mg/dl) +0.8 (p = 0.6) -10 (p < 0.0001) 
TG (mg/dl) -12.5 (p<0.0001) -3 (p=0.1) 
 
DISCUSSION: 
Group A 
Moxonidine 0.3 mg per day in group A resulted in 
statistically significant fall in levels of SBP and DBP at 
12 weeks (Table III). Fall in both these parameters was 
slightly more as reported by Sanjuliani et al
11
 at the end 
of 12 weeks. BP goal to achieve SBP <140 mm Hg and 
DBP < 90 was attained in 24 patients (80%) in group A.  
Again, a fall of 11.5% in levels of fasting plasma 
insulin was observed in group ‘A’ while Sanjuliani et 
al
11
 reported a fall of 19 %. FBG level falls by 4.4 % at 
the end of 12 weeks which are slightly more (5.76 %) as 
stated by Jose Abellan et al.
12 
 While HOMA-IR value 
drops by 7.0 % in present study, a fall of 13 % was 
observed by Sanjuliani et al
11
 (Table III). 
A significant reduction of 12.5 % in TG levels was 
observed after a treatment of 12 weeks(Table III) and 
Sanjuliani et al
11
 stated a reduction of 10.3 % in the 
levels of TG.  
Group B 
Telmisartan 40 mg per day in group B resulted in 
statistically significant fall in levels of SBP and DBP at 
12 weeks (Table III). With Telmisartan, a mean fall of 
11 mmHg in SBP and 5 mmHg in DBP was observed in 
present study while a mean fall of 16 mmHg in SBP and 
6 mmHg in DBP was reported by An Doc Jung et al.
13
 
Telmisartan successfully achieved BP goal of SBP <140 
mm Hg and DBP < 90 in 20 patients (
˷
 67%) in group 
B. 
FBG level fall by 3.7 % (Table III) and  Nagel JM et 
al
14 
 reported a fall by 3.8 %. In FPI levels after 12 
weeks of treatment a significant reduction of 0.4 µU/ml 
(5%) (Table III) was observed while Nagel JM et al
14   
declared a mean fall of 2.3 µU/ml. 
Fall in HOMA-IR value was 7.2 % (Table III) Whereas, 
this fall was more as stated by Nagel JM et al
14
 (16%). 
Telmisartan significantly reduced TC levels by 8% and 
LDL-C levels by 10 % (Table III) and a reduction by 
8.95 % in the levels of TC and 11.5 % in levels of LDL-
C after 12 weeks of treatment was declared by Nagel 
JM et al.
14 
Comparison of Moxonidine vs Telmisartan:- On 
comparing moxonidine and telmisartan it was found 
that moxonidine was better antihypertensive than 
telmisartan. Moxonidine also resulted in achievement of 
goal for blood pressure in more number of patients as 
compared to telmisartan. (Table IV) 
 
TABLE IV: Blood Pressure control with Moxonidine versus Telmisartan  
Test values BP control with Drug Group A vs B 
SBP DBP 
p-value p = 0.02  p = 0.001 
 
It has been seen that both the drugs were equivalent in 
improving the parameters of insulin resistance. But their 
effects were variable on the different parameters of lipid 
profile. Telmisartan was found to be more effective in 
reducing TC and LDL-C than moxonidine, whereas, 
moxonidine was more effective in reducing TG levels 
than telmisartan. 
Clinical assessment and blood tests of the patients had 
not shown any serious adverse events during the trial, 
indicated that these drugs were well tolerated by those 
patients and none of the patients were withdrawn during 
it. Mild side effects were seen like sedation in 13% (4) 
patients, dryness of mouth in 10 % (3) patients and 
headache in 6 % patients in group A (Moxonidine) and 
dry cough in 13 % (4) patients in group B 
(Telmisartan). 
There is a need to confirm the result on the basis of 
larger trial so that we could better treat the hypertensive 
patients according to India’s socio-cultural scenario. 
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CONCLUSION: 
Moxonidine was found to be slightly better 
antihypertensive than telmisartan as the desired goal of 
blood pressure was achieved in more number of patients 
with moxonidine therapy. Both the drugs were 
equivalent in improvement of insulin resistance. 
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